CABOMETYX (Ipsen Pty Ltd)
Product name
CABOMETYX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
40 working days (120 COR-A)
Active ingredients
cabozantinib (S)-malate
Registration type
EOI
Indication
CABOMETYX is now also indicated for the treatment of advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk